Login to Your Account

Pharma: Clinic roundup

Thursday, May 1, 2014
Teva Pharmaceutical Industries Ltd., of Jerusalem, reported positive results from a pivotal phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription